Hims & Hers has a GLP-1 weight loss pill -- and it's the cheapest one out there.

Late last year, Lilly was the first pharmaceutical stock to reach a $1 trillion valuation.

Eli Lilly reports fourth-quarter earnings and revenue that handily top expectations and issues solid guidance.

Historical evidence indicates that abrupt market fluctuations can affect any corporation, regardless of its perceived dominance.

Eli Lilly and Company earnings beat lifts stock: revenue/EPS beat guidance, and the 2026 outlook looks strong, but watch ...

Eli Lilly has outperformed the broader market over the past year, and analysts remain highly bullish about the stock’s ...

Eli Lilly's stock surged Wednesday while shares of weight-loss rival Novo Nordisk slumped, widening the gap between the drugmakers.

Eli Lilly’s Q4 beat and bullish 2026 guidance highlight GLP-1 strength from Mounjaro/Zepbound, supporting a $1240–1300 target ...

Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The company still has a robust business that is delivering excellent results and ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Both companies may succeed in this industry.